SEC Company Response from Processa Pharmaceuticals, Inc. (PCSA) (CIK 0001533743) (PCSA) — Nov 7, 2018

Processa Pharmaceuticals, Inc. (PCSA) (CIK 0001533743)
Date: Nov. 7, 2018 · CIK: 0001533743 · Accession: 0001493152-18-015299

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-226428

Date

Nov. 7, 2018

Author

Chief

Form

CORRESP

Company

Processa Pharmaceuticals, Inc. (PCSA) (CIK 0001533743)

Letter

Processa Pharmaceuticals, Inc.

Coca Cola Drive, Suite 106,

Hanover, Maryland 21076

November 7, 2018

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, NE

Washington, D.C. 20549

Attention: Ms. Dorrie Yale

Re: Processa Pharmaceuticals, Inc.

Registration Statement on Form S-1 (Registration No. 333-226428)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Processa Pharmaceuticals, Inc. (the “Registrant”), hereby requests acceleration of effectiveness of its above-referenced Registration Statement to 4:30 P.M., Eastern time, on November 9, 2018, or as soon as practicable thereafter. The Registrant respectfully requests that you notify Neda Sharifi of Foley & Lardner LLP of such effectiveness by a telephone call to (904) 359-8719.

Very truly yours,
Processa Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

Processa
Pharmaceuticals, Inc.

7380
Coca Cola Drive, Suite 106,

Hanover,
Maryland 21076

November
7, 2018

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, NE

Washington,
D.C. 20549

Attention:
Ms. Dorrie Yale

    Re:
    Processa
    Pharmaceuticals, Inc.

    Registration
    Statement on Form S-1 (Registration No. 333-226428)

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Processa Pharmaceuticals, Inc. (the “Registrant”),
hereby requests acceleration of effectiveness of its above-referenced Registration Statement to 4:30 P.M., Eastern time, on November
9, 2018, or as soon as practicable thereafter. The Registrant respectfully requests that you notify Neda Sharifi of Foley &
Lardner LLP of such effectiveness by a telephone call to (904) 359-8719.

    Very truly yours,

    Processa Pharmaceuticals, Inc.

    By:

    /s/
    David Young

     David
    Young, Pharm.D., Ph.D.

     Chief
    Executive Officer

SecProbe.io